BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-03-31
Target enrollment:
Participant gender:
Summary
Although chemotherapy is the primary treatment option for small cell lung cancer (SCLC),
longterm survival is rare. SCLC is initially chemosensitive, but rapidly relapses in a
chemoresistant form with an overall survival of <5%. Consequently, novel therapies are
urgently required and will likely arise from an improved understanding of the disease
biology. Some preclinical studies have showed that fibroblast growth factor-2 induces
proliferation and